Alliance Pharma Share Discussion Threads

[tomzimerman] 05/4/2024 08:43

Spamming everyone you can today Lloyds Bank (LLOY) 'On Topic only' - Thread - Post 28347 LLOY Lloyds Banking Group Plc Blackhorse23 05 Apr 2024 09:30https://www.londonstockexchange.com/news-article/APH/full-year-trading-update/16307097# GELION - Global Energy Storage # - Post 47 GELN Gelion Plc Blackhorse23 05 Apr 2024 09:28https://www.londonstockexchange.com/news-article/APH/full-year-trading-update/16307097Microlise: Transport telematics to optimize fleet operations efficiency - Post 61 SAAS Microlise Group Plc Blackhorse23 05 Apr 2024 09:28https://www.londonstockexchange.com/news-article/APH/full-year-trading-update/16307097

[blackhorse23] 05/4/2024 08:22

Buying opportunity at this dip

[the imperialist] 05/4/2024 08:08

Is that the catalyst that takes this into the 20s?

[blackhorse23] 05/4/2024 07:59

https://www.londonstockexchange.com/news-article/APH/full-year-trading-update/16307097

[blackhorse23] 05/4/2024 07:59

Alliance confirms that the details provided in the full year trading update on 29 January 2024 remain accurate.

[blackhorse23] 05/4/2024 07:53

Financial summaryThe Group delivered record see-through1 revenues in the Period of £182.7m (FY22: £172.0m), up 6% versus the prior period and up 7% at constant exchange rates ("CER"). Excluding sales from ScarAway and the US rights to Kelo-Cote in Q1 23, both acquired in March 2022 (the "US Acquisition"), like-for-like see-through revenues increased 6% CER. Continued strong consumer demand, particularly in China, drove significant recovery in Kelo-Cote franchise revenues in H2, leading to FY23 revenues of £63.2m, up 29% CER (FY22: £50.0m). Nizoral revenues increased 3% CER to £21.7m (FY22: £21.8m) whilst Amberen revenues declined 6% CER on an underlying basis (excluding the leading discount store account that was lost in 2022) and decreased 25% CER to £11.2m (FY22: £14.9m) on a reported basis. With Other Consumer brands up 5% CER to £40.3m (FY22: £38.4m), total see-through Consumer Healthcare revenues increased 11% CER to £136.4m. Prescription Medicine revenues were stable at £46.3m (FY22: £46.8m), reflecting a strong recovery in H2 as expected, as previously out of stock products became available. Underlying profit for the Period is anticipated to be in-line with market expectations. Cash and debtFree cash flow in the Period rose 34% to £21.1m (FY22: £15.8m) and net debt reduction continued, falling to £92.4m at 31 December 2023 (31 December 2022: £102.0m). Group leverage2 (as at 31 December 2023) is expected to be significantly below that at 30 June 2023 (2.7x), and in-line with previous guidance.

[blackhorse23] 05/4/2024 07:52

Has not changed the guidelines of the results published on 29th jan which is showing business is booming

[blackhorse23] 05/4/2024 07:51

No volume will go up today

[queenbreguet] 05/4/2024 06:32

Buy on the coming dip. DYOR

[tomzimerman] 05/4/2024 06:14

Not a good start to the day

[davemac3] 05/4/2024 06:10

Changed results date, didn’t they know auditors need more time yesterday? Poor

[blackhorse23] 04/4/2024 08:55

HSBC ungraded as buy

[blackhorse23] 04/4/2024 08:51

Looking bullish

[blackhorse23] 03/4/2024 13:13

Financial summaryThe Group delivered record see-through1 revenues in the Period of £182.7m (FY22: £172.0m), up 6% versus the prior period and up 7% at constant exchange rates ("CER"). Excluding sales from ScarAway and the US rights to Kelo-Cote in Q1 23, both acquired in March 2022 (the "US Acquisition"), like-for-like see-through revenues increased 6% CER. Continued strong consumer demand, particularly in China, drove significant recovery in Kelo-Cote franchise revenues in H2, leading to FY23 revenues of £63.2m, up 29% CER (FY22: £50.0m). Nizoral revenues increased 3% CER to £21.7m (FY22: £21.8m) whilst Amberen revenues declined 6% CER on an underlying basis (excluding the leading discount store account that was lost in 2022) and decreased 25% CER to £11.2m (FY22: £14.9m) on a reported basis. With Other Consumer brands up 5% CER to £40.3m (FY22: £38.4m), total see-through Consumer Healthcare revenues increased 11% CER to £136.4m. Prescription Medicine revenues were stable at £46.3m (FY22: £46.8m), reflecting a strong recovery in H2 as expected, as previously out of stock products became available. Underlying profit for the Period is anticipated to be in-line with market expectations.

[wad collector] 03/4/2024 13:01

You continue to plaster BBs with your pretend sales
Blackhorse23 - 03 Apr 2024 - 12:29:37 - 1019 of 1021 Ondo InsurTech - ONDO
What is future of this company? Only health care company I have invested in is APH , looking for another one
Blackhorse23 - 03 Apr 2024 - 12:28:21 - 57465 of 57466 Avacta – Innovative and Disruptive Technologies for Global Health Markets - AVCT
APH [LSE] share price is doing well, excellent profitable healthcare company. Right decision moved from here
Blackhorse23 - 03 Apr 2024 - 12:08:11 - 17989 of 17998 SkinBioTherapeutics PLC - Multi $bn skin health opportunities. - SBTX
Money moving to APH [LSE] , excellent profitable healthcare company.
Blackhorse23 - 03 Apr 2024 - 12:07:45 - 12058 of 12060 Deltex Medical - a British success story! - DEMG
Money moving to APH [LSE] , excellent profitable healthcare company



Please stop

[blackhorse23] 03/4/2024 11:02

Keep buying , last chance for you below 40p

[blackhorse23] 03/4/2024 08:13

Keep buying , next week double time

[tomzimerman] 03/4/2024 06:54

You must be due a TR1 here unless your buying 1 share at a time ha ha SUPERDRY - Post 5208 SDRY Superdry Plc Blackhorse23 02 Apr 2024 11:25 1 2Sold at loss & money moving to APH

[tomzimerman] 03/4/2024 06:50

Desperate Westminster Group PLC - Post 1825 WSG Westminster Group Plc Blackhorse23 02 Apr 2024 22:21 1Another company on the way to bankrupt , money moving to APH

[blackhorse23] 02/4/2024 19:44

https://uk.citywire.com/investment_trust_insider/share-prices-and-performance/share-factsheet.aspx?InstrumentID=164220&utm_medium=website&utm_source=citywire_it_insider&utm_campaign=article-related-share

[tomzimerman] 02/4/2024 19:38

Bought more 🤣🤣🤣 Again?

[the imperialist] 02/4/2024 16:16

You still have to break into the 20s before going higher. That’s how markets work.

Buy order set for 19p.

[buoycat] 02/4/2024 14:48

This 'dip' so far lasted about a year. And that's after the previous dip.

[blackhorse23] 02/4/2024 08:44

Bought some at this dip